Treating clostridium difficile infection with fecal microbiota transplantation

Johan S. Bakken, Thomas Borody, Lawrence J. Brandt, Joel V. Brill, Daniel C. Demarco, Marc Alaric Franzos, Colleen Kelly, Alexander Khoruts, Thomas Louie, Lawrence P. Martinelli, Thomas A. Moore, George Russell, Christina Surawicz

Research output: Contribution to journalArticlepeer-review

757 Scopus citations


Clostridium difficile infection is increasing in incidence, severity, and mortality. Treatment options are limited and appear to be losing efficacy. Recurrent disease is especially challenging; extended treatment with oral vancomycin is becoming increasingly common but is expensive. Fecal microbiota transplantation is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of fecal microbiota transplantation.

Original languageEnglish (US)
Pages (from-to)1044-1049
Number of pages6
JournalClinical Gastroenterology and Hepatology
Issue number12
StatePublished - Dec 2011

Bibliographical note

Funding Information:
Conflicts of interest These authors disclose the following: Thomas Borody has patents in the field of fecal transplantation. Alexander Khoruts receives funding from the Minnesota Medical Foundation and NIH grant 1R21AI091907 . The remaining authors disclose no conflicts.


  • Clostridium difficile
  • Diarrhea
  • Fecal Enema
  • Microbiota
  • Recurrent Infection
  • Transplantation


Dive into the research topics of 'Treating clostridium difficile infection with fecal microbiota transplantation'. Together they form a unique fingerprint.

Cite this